Exceptional Long-term Response to Immunotherapy in an African American Man With STK11/TP53/RB1 -Mutated Metastatic Lung Adenocarcinoma
Journal of Investigative Medicine High Impact Case Reports · 2025
DOI: 10.1177/23247096251346830 ↗Kurz gefasst
Fallbericht in der Zeitschrift Journal of Investigative Medicine High Impact Case Reports, 2025. Verfasst von Yaolin Zhou und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Immunotherapy, Lung Neoplasms. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Immunotherapy has become the standard of care for advanced and resectable lung cancer, and specific mutations may predict immunotherapy response. For example, STK11 mutations, which are more common in African American patients, are associated with immunotherapy resistance. A 68-year-old African American man with stage IIIB lung adenocarcinoma with mediastinal lymph node involvement progressed on first-line concurrent carboplatin-based chemoradiotherapy. Molecular testing of the patient’s subcarinal lymph node tissue revealed STK11 S216F, TP53 R273L, and RB1 splice site mutations; high tumor mutation burden (19.0 mutations/Mb); and high PD-L1 22c3 expression (TPS 70%, 2+ intensity). Treatment with carboplatin-based chemotherapy with radiation therapy failed to control the disease, but the patient has tolerated and responded well to intravenous pembrolizumab. Although STK11 mutations are associated with immunotherapy resistance, our patient demonstrated an exceptional and sustained response to immunotherapy for over two years. The patient’s STK11/TP53 co-mutation, along with high TMB and PD-L1 22c3 TPS scores, may help explain his continued responsiveness to immunotherapy and longer survival. Importantly, incorporating genetic ancestry differences in mutation prevalence and the impact of specific mutations and co-mutations, may help ensure the equitable and optimal treatment of all patients with lung cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
- Division of Pulmonary, Critical Care and Sleep Medicine, Appalachian Regional Healthcare, Hazard, KY, USA.
- Division of Hematology-Oncology in the Department of Internal Medicine, Brody School of Medicine, East Carolina University, Greenville, NC, USA.
ORCID-Profile: Yaolin Zhou, Maneesh Gaddam, Sunil Badami
Zitieren
APA
Zhou, Y., Gaddam, M., & Badami, S. (2025). Exceptional Long-term Response to Immunotherapy in an African American Man With STK11/TP53/RB1 -Mutated Metastatic Lung Adenocarcinoma. Journal of Investigative Medicine High Impact Case Reports. https://doi.org/10.1177/23247096251346830
Vancouver
Zhou Y, Gaddam M, Badami S. Exceptional Long-term Response to Immunotherapy in an African American Man With STK11/TP53/RB1 -Mutated Metastatic Lung Adenocarcinoma. Journal of Investigative Medicine High Impact Case Reports. 2025. doi:10.1177/23247096251346830
BibTeX
@article{Zhou2025,
author = {Zhou, Yaolin and Gaddam, Maneesh and Badami, Sunil},
title = {Exceptional Long-term Response to Immunotherapy in an African American Man With STK11/TP53/RB1 -Mutated Metastatic Lung Adenocarcinoma},
journal = {Journal of Investigative Medicine High Impact Case Reports},
year = {2025},
doi = {10.1177/23247096251346830}
}
EUVIMED